Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Gross

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|September 13, 2021
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive DyskinesiaMartha Sajatovic, Stacy Finkbeiner, Amanda Wilhelm, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|April 22, 2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trialsNicholas Gross, Leon S Greos, Eli O Meltzer, et al.
Chest|May 13, 2003
Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse eventsJames K Stoller, Robert Fallat, Mark D Schluchter, et al.
British Journal of Clinical Pharmacology|February 3, 2019
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteersAnne C Baakman, Rob Zuiker, Joop M A van Gerven, et al.
CNS Drugs|January 17, 2025
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington DiseaseSamuel Frank, Claudia M Testa, Jody Goldstein, et al.
Digital Biomarkers|February 26, 2020
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor DevicesMark Forrest Gordon, Igor D Grachev, Itzik Mazeh, et al.
CNS Drugs|October 15, 2022
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudySamuel Frank, Claudia Testa, Mary C Edmondson, et al.
Journal of Clinical Psychopharmacology|June 20, 2024
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Frontiers in Neurology|March 14, 2022
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|September 13, 2021
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive DyskinesiaMartha Sajatovic, Stacy Finkbeiner, Amanda Wilhelm, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|April 22, 2014
Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trialsNicholas Gross, Leon S Greos, Eli O Meltzer, et al.
Chest|May 13, 2003
Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse eventsJames K Stoller, Robert Fallat, Mark D Schluchter, et al.
British Journal of Clinical Pharmacology|February 3, 2019
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteersAnne C Baakman, Rob Zuiker, Joop M A van Gerven, et al.
CNS Drugs|January 17, 2025
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington DiseaseSamuel Frank, Claudia M Testa, Jody Goldstein, et al.
Digital Biomarkers|February 26, 2020
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor DevicesMark Forrest Gordon, Igor D Grachev, Itzik Mazeh, et al.
CNS Drugs|October 15, 2022
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudySamuel Frank, Claudia Testa, Mary C Edmondson, et al.
Journal of Clinical Psychopharmacology|June 20, 2024
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Frontiers in Neurology|March 14, 2022
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
The Lancet. Neurology|December 20, 2018
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Andrew McGarry, Igor D Grachev, et al.
Pageof 4